THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$127.3M

Filings

154

Firms Hired

Active Period

1999–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$8,260,000	6	2
2025	$11,960,000	10	2
2024	$8,250,000	8	2
2023	$10,420,000	9	2
2022	$8,580,000	8	2
2021	$12,490,000	9	2
2020	$7,220,000	8	2
2019	$8,250,000	8	2
2018	$10,370,000	10	2
2017	$6,610,000	10	2
2016	$4,520,000	8	2
2015	$5,180,000	7	2
2014	$3,550,000	4	1
2013	$2,270,000	5	1
2012	$1,802,807	6	1
2011	$1,990,000	6	1
2010	$2,310,000	5	1
2009	$3,370,000	7	1
2008	$1,551,436	5	1
2007	$1,680,000	3	1
2006	$680,000	2	1
2005	$520,000	2	1
2004	$560,000	1	1
2003	$960,000	1	1
2002	$780,000	1	1
2001	—	1	1
2000	$1,538,440	2	1
1999	$1,580,000	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)	$127,252,683	106
WILMER CUTLER PICKERING HALE AND DORR LLP	—	48

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	120
HOUSE OF REPRESENTATIVES	118
Health & Human Services, Dept of (HHS)	96
Centers For Medicare and Medicaid Services (CMS)	82
Congressional Budget Office (CBO)	50
Treasury, Dept of	48
Executive Office of the President (EOP)	47
Labor, Dept of (DOL)	33
Commerce, Dept of (DOC)	22
White House Office	20
State, Dept of (DOS)	17
U.S. Trade Representative (USTR)	15
Justice, Dept of (DOJ)	9
Federal Trade Commission (FTC)	8
Natl Economic Council (NEC)	5
Office of Management & Budget (OMB)	5
Transportation, Dept of (DOT)	4
Vice President of the U.S.	4
Food & Drug Administration (FDA)	2
Office of the Vice President of the United States	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	113
Medicare/Medicaid	Medicare/Medicaid	105
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	67
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	44
Pharmacy	Pharmacy	44
Insurance	Insurance	36
Defense	Defense	34
Trade (domestic/foreign)	Trade (domestic/foreign)	28
Retirement	Retirement	12
Torts	Torts	10
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	8
Postal	Postal	5
Budget/Appropriations	Budget/Appropriations	4
Immigration	Immigration	4
Foreign Relations	Foreign Relations	3
Computer Industry	Computer Industry	1
Environment/Superfund	Environment/Superfund	1
Economics/Economic Development	Economics/Economic Development	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5378118th Congress

Lower Costs, More Transparency Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: H.R. 5378

H.R. 2214119th Congress

DRUG Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: H.R.2214

H.R. 3838119th Congress

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Client expense: $3,490,000 · Firm income: —

Matched citations: H.R. 3838

H.R. 5582119th Congress

Patients Deserve Price Tags Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: H.R. 5582

Show 21 more cited filings

H.R. 6400119th Congress

Rx ACCESS Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Client expense: $3,490,000 · Firm income: —

Matched citations: HR. 6400

H.R. 7148119th Congress

Consolidated Appropriations Act, 2026

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: H.R.7148

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S. 1339

S. 1542118th Congress

DRUG Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S. 1542

S. 2296119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S2296

S. 2355119th Congress

Patients Deserve Price Tags Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S. 2355

S. 4106119th Congress

Rx ACCESS Act

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S. 4106

S. 526119th Congress

Pharmacy Benefit Manager Transparency Act of 2025

2026 · first_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Client expense: $3,490,000 · Firm income: —

Matched citations: S.526

H.R. 5378118th Congress

Lower Costs, More Transparency Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,670,000 · Firm income: —

Matched citations: H.R. 5378

H.R. 2214119th Congress

DRUG Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,670,000 · Firm income: —

Matched citations: H.R.2214

H.R. 247119th Congress

Health Care Affordability Act of 2025

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.

Client expense: $1,670,000 · Firm income: —

Matched citations: H.R. 247

H.R. 3838119th Congress

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.

Client expense: $1,670,000 · Firm income: —

Matched citations: H.R. 3838

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,670,000 · Firm income: —

Matched citations: S. 1339

S. 1542118th Congress

DRUG Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,670,000 · Firm income: —

Matched citations: S. 1542

S. 2296119th Congress

National Defense Authorization Act for Fiscal Year 2026

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.

Client expense: $1,670,000 · Firm income: —

Matched citations: S. 2296

S. 526119th Congress

Pharmacy Benefit Manager Transparency Act of 2025

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,670,000 · Firm income: —

Matched citations: S.526

S. 864119th Congress

HELP Copays Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.

Client expense: $1,670,000 · Firm income: —

Matched citations: S. 864

H.R. 5378118th Congress

Lower Costs, More Transparency Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,640,000 · Firm income: —

Matched citations: H.R. 5378

H.R. 2214119th Congress

DRUG Act

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Client expense: $1,640,000 · Firm income: —

Matched citations: H.R.2214

H.R. 247119th Congress

Health Care Affordability Act of 2025

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.

Client expense: $1,640,000 · Firm income: —

Matched citations: H.R. 247

H.R. 3838119th Congress

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

2025 · fourth_quarter · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.

Client expense: $1,640,000 · Firm income: —

Matched citations: H.R. 3838

Source: Senate LDA

THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) — Lobbying Disclosure | Poliscope